Library of phosphoinositide-3-kinase (PI3K) inhibitors to screen against various NTDs

Status
On going
Start date
Start stage
Screening
End stage
Screening
Disease
Chagas disease
Human African trypanosomiasis (HAT)
Research areas
Basic research
Drug

Merck KGaA, Darmstadt, Germany will provide a University of California, San Diego (UCSD) investigator with a targeted library of phosphoinositide-3-kinase (PI3K) inhibitors. The UCSD investigator will screen these inhibitors for activity against the causative agents of Chagas disease, human African trypanosomiasis, and leishmaniasis.